Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) investors concerning the Company's possible violations of federal securities laws. On April 4, 2024, AbbVie disclosed that its prior financial guidance excluded the impact of acquired In-Process Research and Development (“IPR&D”) and milestone expense. The Company also disclosed that its earnings for the first quarter of 2024 “are expect.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors

AbbVie's stock has outperformed the market over the past decade, with a 248.90% appreciation. Despite losing patent protection for Humira, which accounted for 37% of revenue in 2022, AbbVie remains undervalued and continues to grow its dividend. AbbVie's recent acquisitions and robust pipeline position the company for future growth and expansion.

AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67%

-     Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine -     Seventy percent of subjects achieved ≥50% reduction in monthly migraine days at Weeks 13-16 and this was consistent during the 48 weeks of open-label treatment -      Findings will be showcased in an oral presentation at the American Academy of Neurology (AAN) Annual Meeting Scientific Platform Session for Emerging Science NORTH CHICAGO, Ill. , April 12, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced an interim analysis of an ongoing Phase 3, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine.

AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine

CRISPR Therapeutics

Johnson & Johnson

Biotech stocks were among the worst performers in 2023. And so far in 2024, investors are still waiting on the recovery rally.

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On April 4, 2024, AbbVie disclosed that its prior financial guidance excluded the impact of acquired In-Process Research and Development (“IPR&D”) and milestone expense. The Compan.

The Law Offices of Frank R. Cruz Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors

From the makers of BOTOX ® Cosmetic, two new SkinMedica ®  acne products help address skin blemishes and can be combined with in-office DiamondGlow ® IRVINE, Calif. , April 9, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the launch of two new products from SkinMedica® by the makers of BOTOX® Cosmetic.

SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne

Bristol-Myers

AbbVie's dividend payout has more than tripled over the past decade, and it could soar much further in the decade ahead. Bristol Myers Squibb offers a juicy 4.7% dividend yield at recent prices.

3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade

In the latest trading session, AbbVie (ABBV) closed at $169.80, marking a -0.12% move from the previous day.

Here's Why AbbVie (ABBV) Fell More Than Broader Market

AbbVie's stock price fell by about 7% last week after the company revised its full-year and Q1 guidance downward.

AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision

We believe that the pharmaceuticals bellwether Johnson & Johnson (NYSE: JNJ) is currently a better pick over its peer AbbVie (NYSE: ABBV). AbbVie ABBV trades at a higher valuation of 5.5x trailing revenues, compared to 4.6x for JNJ.

Is Johnson & Johnson Stock A Better Pick Over AbbVie?

Gilead Sciences

Pfizer

AbbVie offers one of the most attractive dividends around. Gilead Sciences provides stability and consistency to income investors.

3 No-Brainer Dividend Stocks to Buy in April

Altria

Morgan Stanley

PepsiCo

Philip Morris

Exxon Mobil

The topic of passive income is popular these days. Investors, consumers, and many other individuals are curious about any method that can produce income without work.

Passive Income Perfection: 7 Dividend Stocks to Generate $50,000 Per Year

NORTH CHICAGO, Ill. , April. 4, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2024 financial results on Friday, April 26, 2024, before the market opens.

AbbVie to Host First-Quarter 2024 Earnings Conference Call

Amgen

Eli Lilly

As we look forward to celebrating World Health Day on April 7th, these are the top three healthcare US companies we think you should be watching for your financial health.  1. Lilly (Eli) & Co.

Top three US healthcare stocks to buy in April

Emerson Electric

Nexstar Media Group

Verizon

I present you our framework for buying and selling dividend stocks. It follows our simple motto of buy low, sell high, get paid to wait. Here are 2 brilliant buys and 2 smart sells for Q2 2024.

2 Strong Dividend Buys And 2 Sells For Q2 2024

Offering $200 Off the First CoolSculpting® Treatment IRVINE, Calif. , April 3, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) is announcing its second annual CoolMonth celebration featuring CoolSculpting® Elite.

Allergan Aesthetics Announces the Return of CoolMonth with CoolSculpting®

Sempra Energy

The big money might be feeling a bit queasy about overexposure to risk-on assets, presenting a framework to follow regarding the best stocks to buy in April. As I've mentioned many times before, technology-related securities saw an outflow recently of $4.4 billion.

The 3 Best Stocks to Buy in April 2024

e.l.f. Beauty

Businesses across a range of industries can do well in both bull and bear markets. AbbVie is dealing with some business changes, but its existing products and burgeoning pipeline could usher in a new era of growth.

Got $3,000? 2 Monster Growth Stocks to Buy Right Now Without Hesitation

The latest trading day saw AbbVie (ABBV) settling at $180.76, representing a -0.74% change from its previous close.

AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know

HCA Healthcare

Intuitive Surgical

Novo Nordisk

UnitedHealth Group

Vertex Pharmaceuticals

These seven healthcare companies are industry and market leaders. They generally present excellent long-term prospects, too.

Meet The "Magnificent Seven" of Healthcare Stocks

Canadian Natural Resources

Essential Properties Realty Trust Inc

Extra Space Storage

Interpublic Group of Companies

Coca-Cola Femsa SAB de CV

NextEra Energy

SPDR S&P 500 ETF Trust

I rank a selection of Dividend Radar stocks and present the ten top-ranked stocks for consideration.

10 Dividend Growth Stocks: March 2024

Medtronic

Now that it's focused on just medical technology and pharmaceuticals, Johnson & Johnson's pace of annual dividend raises could accelerate. Medtronic is the largest publicly traded medical device manufacturer, and it offers a 3.3% yield at recent prices.

3 Reliable Dividend Growth Stocks With Yields Above 3% That You Can Buy Now and Hold for at Least a Decade

Coca-Cola

Whether an investor seeks steady income or long-term growth, the dividend king stocks are a great option. Dividend bearing companies are generally stable, well-established and consistently profitable.

Long Live the Dividend Kings: 3 Top Picks to Build an Income Portfolio

AutoZone

Core Laboratories Inc

Compass Minerals

Corteva Inc

Estee Lauder

Etsy

Honeywell

Hershey

International Flavors & Fragrances

Kenvue

McDonald's

MarketAxess Holdings

Motorola Solutions

NIKE

We share the heat map of the most investable candidates that may be worth your time for further analysis.

U.S. Wide-Moat Stocks On Sale - The March 2024 Heat Map

News for AbbVie Stock (ABBV)